Literature DB >> 19920165

Association of B-type natriuretic Peptide levels with estimated glomerular filtration rate and congestive heart failure.

Carmen L Wiley1, Sean P Switzer, Richard L Berg, Ingrid Glurich, Richard A Dart.   

Abstract

BACKGROUND: The causes of elevated B-Type natriuretic peptide (BNP) levels are multifactorial. Renal dysfunction has been shown to affect BNP levels in some studies and the diagnostic value of BNP levels in the presence of chronic kidney disease has been questioned. Prior studies have involved small patient populations with variable outcomes noted. This study evaluated the association of BNP levels with an estimated glomerular filtration rate (eGFR) and presence or absence of congestive heart failure (CHF).
METHODS: A retrospective, cross-sectional study in which medical records were electronically screened, identified patients with a BNP level and serum creatinine measurement on the same day between December 2002 and March 2006.
RESULTS: Of 1739 eligible patients, 537 were positive for CHF and 1202 were negative for CHF by our criteria. There was a clear trend for BNP to be higher with the advancement of CHF, as determined by New York Heart Association (NYHA) classification (P<0.001). Median BNP levels increased from 65 pg/mL in patients without CHF to 496 pg/mL in patients with NYHA class IV CHF (P <0.001), and there was a strong inverse association with eGFR (P <0.001).
CONCLUSION: BNP levels show a strong inverse association with eGFR in both CHF and non-CHF patients. Currently best practice at most institutions involves use of BNP cutoff diagnostic levels not adjusted for eGFR. The data presented underlines that eGFR is a significant confounder of BNP measurement especially when renal status is compromised and interpretation of clinical significance in the presence of elevated BNP measures should take renal status into consideration.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19920165      PMCID: PMC2842335          DOI: 10.3121/cmr.2009.867

Source DB:  PubMed          Journal:  Clin Med Res        ISSN: 1539-4182


  32 in total

1.  Direct comparison of B-type natriuretic peptide (BNP) and amino-terminal proBNP in a large population of patients with chronic and symptomatic heart failure: the Valsartan Heart Failure (Val-HeFT) data.

Authors:  Serge Masson; Roberto Latini; Inder S Anand; Tarcisio Vago; Laura Angelici; Simona Barlera; Emil D Missov; Aldo Clerico; Gianni Tognoni; Jay N Cohn
Journal:  Clin Chem       Date:  2006-06-15       Impact factor: 8.327

2.  Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate.

Authors:  Andrew S Levey; Josef Coresh; Tom Greene; Lesley A Stevens; Yaping Lucy Zhang; Stephen Hendriksen; John W Kusek; Frederick Van Lente
Journal:  Ann Intern Med       Date:  2006-08-15       Impact factor: 25.391

Review 3.  Natriuretic peptides.

Authors:  Lori B Daniels; Alan S Maisel
Journal:  J Am Coll Cardiol       Date:  2007-12-18       Impact factor: 24.094

4.  Use of an electronic medical record for the identification of research subjects with diabetes mellitus.

Authors:  Russell A Wilke; Richard L Berg; Peggy Peissig; Terrie Kitchner; Bozana Sijercic; Catherine A McCarty; Daniel J McCarty
Journal:  Clin Med Res       Date:  2007-03

5.  Natriuretic peptides in chronic kidney disease.

Authors:  Rajat Tagore; Lieng H Ling; Hong Yang; Hla-Yee Daw; Yiong-Huak Chan; Sunil K Sethi
Journal:  Clin J Am Soc Nephrol       Date:  2008-07-16       Impact factor: 8.237

6.  Impact of renal disease on natriuretic peptide testing for diagnosing decompensated heart failure and predicting mortality.

Authors:  Christopher R deFilippi; Stephen L Seliger; Susan Maynard; Robert H Christenson
Journal:  Clin Chem       Date:  2007-06-22       Impact factor: 8.327

7.  Introduction of metoprolol increases plasma B-type cardiac natriuretic peptides in mild, stable heart failure.

Authors:  Mark E Davis; A Mark Richards; M Gary Nicholls; Timothy G Yandle; Christopher M Frampton; Richard W Troughton
Journal:  Circulation       Date:  2006-02-13       Impact factor: 29.690

8.  Plasma brain natriuretic peptide-guided therapy to improve outcome in heart failure: the STARS-BNP Multicenter Study.

Authors:  Patrick Jourdain; Guillaume Jondeau; François Funck; Pascal Gueffet; Alain Le Helloco; Erwan Donal; Jean F Aupetit; Marie C Aumont; Michel Galinier; Jean C Eicher; Alain Cohen-Solal; Yves Juillière
Journal:  J Am Coll Cardiol       Date:  2007-04-02       Impact factor: 24.094

Review 9.  Cardiovascular disease in patients with chronic renal impairment: role of natriuretic peptides.

Authors:  Marc Vanderheyden; Jozef Bartunek; Gerasimos Filippatos; Marc Goethals; Bruno Van Vlem; Alan Maisel
Journal:  Congest Heart Fail       Date:  2008 Jul-Aug

10.  Relationship between serum brain natriuretic peptide and heart function in patients with chronic kidney disease.

Authors:  Jae Won Yang; Min Soo Kim; Jae Seok Kim; Jong Myoung Yoo; Seung Tae Han; Bi Ro Kim; Yun Deok Kim; Jeong Wook Choi; Seung Ok Choi; Byoung Geun Han
Journal:  Korean J Intern Med       Date:  2008-12       Impact factor: 2.884

View more
  9 in total

1.  B-type natriuretic peptide-guided risk assessment for postoperative complications in lung cancer surgery.

Authors:  Takashi Nojiri; Masayoshi Inoue; Yasushi Shintani; Yukiyasu Takeuchi; Hajime Maeda; Toshimitsu Hamasaki; Meinoshin Okumura
Journal:  World J Surg       Date:  2015-05       Impact factor: 3.352

2.  Relationship of brain natriuretic peptide concentrations to left ventricular function and adverse outcomes in children with end-stage renal disease undergoing hemodialysis.

Authors:  Sana Ouali; Iheb Bougmiza; Saoussen Abroug; Asma Omezzine; Helmi Ben Salem; Elyes Neffeti; Fahmi Remedi; Ali Bouslema; Abdelaziz Harabi; Essia Boughzela
Journal:  Pediatr Cardiol       Date:  2011-02-20       Impact factor: 1.655

3.  Physical exercise with weight reduction lowers blood pressure and improves abnormal left ventricular relaxation in pharmacologically treated hypertensive patients.

Authors:  Giuseppe Cocco; Stefano Pandolfi
Journal:  J Clin Hypertens (Greenwich)       Date:  2010-10-06       Impact factor: 3.738

4.  Chapter 4: Other complications of CKD: CVD, medication dosage, patient safety, infections, hospitalizations, and caveats for investigating complications of CKD.

Authors: 
Journal:  Kidney Int Suppl (2011)       Date:  2013-01

5.  Chapter 5: Referral to specialists and models of care.

Authors: 
Journal:  Kidney Int Suppl (2011)       Date:  2013-01

6.  Cardiac magnetic resonance defines mechanisms of sex-based differences in outcomes following cardiac resynchronization therapy.

Authors:  Derek J Bivona; Srikar Tallavajhala; Mohamad Abdi; Pim J A Oomen; Xu Gao; Rohit Malhotra; Andrew Darby; Oliver J Monfredi; J Michael Mangrum; Pamela Mason; Sula Mazimba; Michael Salerno; Christopher M Kramer; Frederick H Epstein; Jeffrey W Holmes; Kenneth C Bilchick
Journal:  Front Cardiovasc Med       Date:  2022-09-15

7.  Serum NGAL, BNP, PTH, and albumin do not improve glomerular filtration rate estimating formulas in children.

Authors:  Julie Mouron-Hryciuk; François Cachat; Paloma Parvex; Thomas Perneger; Hassib Chehade
Journal:  Eur J Pediatr       Date:  2021-03-10       Impact factor: 3.183

8.  Myocardial dysfunction and chronic heart failure in patients with long-lasting type 1 diabetes: a 7-year prospective cohort study.

Authors:  Ewa Konduracka; Grazyna Cieslik; Danuta Galicka-Latala; Pawel Rostoff; Artur Pietrucha; Pawel Latacz; Grzegorz Gajos; Maciej T Malecki; Jadwiga Nessler
Journal:  Acta Diabetol       Date:  2013-01-30       Impact factor: 4.280

9.  Associations Between the Cyclic Guanosine Monophosphate Pathway and Cardiovascular Risk Factors: MESA.

Authors:  Wendy Ying; Di Zhao; Pamela Ouyang; Vinita Subramanya; Dhananjay Vaidya; Chiadi E Ndumele; Eliseo Guallar; Kavita Sharma; Sanjiv J Shah; David A Kass; Ron C Hoogeveen; Joao A Lima; Susan R Heckbert; Christopher R deFilippi; Wendy S Post; Erin D Michos
Journal:  J Am Heart Assoc       Date:  2019-12-16       Impact factor: 5.501

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.